Ved gennemgangen af de forskellige patientgrupper i denne undersøgelse viste det sig dog, at behandling med Ventavis kun havde gavnlig virkning hos patienter med primær pulmonal hypertension (klasse III).
However, when looking at different groups of patients in this study, a benefit of Ventavis that would be relevant for patients was only shown in patients with class III primary pulmonary hypertension.